Thursday, May 30, 2013
(11:00 a.m. – 1:00 p.m.)
PhRMA Boardroom
950 F Street, Suite 300, Washington, D.C.
Dial In: 1-800-875-3456  
Verbal Passcode:  VC20743
“Advancing Patient-Focused Drug Development and Benefit-Risk Assessment”
We are pleased to announce the first in a series of informational briefings for stakeholders who share our commitment to scientific advancements that bring new medicines to patients in a timely manner.  The first of these briefings will focus on the FDA’s consideration of the benefits and risks of new medicines, a core component of the regulatory review process and key to advancing patient-focused drug development.
Following brief presentations from recognized experts in the field of benefit-risk and patient-focused drug development, we invite attendees to engage in an open discussion of these important issues.
Guest Speakers:
Marilyn Metcalf, Senior Director, Benefit Risk Evaluation, GlaxoSmithKline
Kristin Van Goor, Senior Director, Scientific and Regulatory Affairs, PhRMA
Tim Franson, FaegreBD
Webinar Instructions

For participating by webinar:

1. Web access: log on for web access to view the Power Point presentations.

2. Audio access: call into our conference service to access the audio component of this program.

• About 10 minutes before our start time, please log into

• In the box “Join Conference,” enter participant code 22194453

• Enter your name, company and email address

• Click start

• Note that you may be asked to download a plug-in

• To participant, the dial-in number is US Toll Free 1-800-875-3456 with verbal passcode VC20743

• To ask a question, press *1

• To remove the question from the question queue, press #